Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin
Aliment Pharmacol Ther 31, 1346–1353 Summary Background The optimal dose of ribavirin to be used in combination with Peg‐IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been established. Aim To explore the relationship between starting ribavirin doses, expressed as mg...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-06, Vol.31 (12), p.1346-1353 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!